VANCOUVER, British Columbia, May 29, 2019 (GLOBE NEWSWIRE) --

EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") today reported the Company’s consolidated interim financial results for the second quarter ended March 31, 2019.

Consolidated Financial Performance:

($ ‘000s)Three months ended March 31, Six months ended March 31,
 2019 2018 Change
%
 2019 2018 Change
%
        
Revenues8,773 4,172 110% 16,579 8,691 91%
Direct costs5,653 2,877 96% 10,422 5,970 75%
  Gross margin3,120 1,295 141% 6,157 2,721 126%
        
Operating expenses       
General and administration1,049 606 73% 2,047 1,199 71%
Sales and marketing1,084 683 59% 2,060 1,273 62%
Research and development369 297 24% 710 569 25%
 2,502 1,586 58% 4,817 3,041 58%
Net income (loss) after taxes(224)(519)(57%) (239)(916)(74%)
Adjusted EBITDA*1,002 4 n/a 2,165 319 579%
Loss per share – basic and diluted(0.00) (0.01)  (0.00) (0.01) 
        

 * Adjusted EBITDA is a non-IFRS financial measure. Refer to the disclosure below regarding non-IFRS financial measures below and in the Company’s MD&A.

EnWave’s interim condensed consolidated financial statements and MD&A are available on SEDAR at www.sedar.com and on the Company’s website www.enwave.net.

Key Financial Highlights for Q2 (expressed in ‘000s):

Significant Accomplishments:

Investor Relations Agreement:

The Company retained Mr. Jochen Staiger of Swiss Resource Capital (“SRC”) to provide investor relations services for the Company in the European capital markets.  SRC will broaden awareness of EnWave’s investment case in Europe with retail and institutional investors. SRC will be remunerated CHF 5,000 per month (CAD $6,650) for the twelve-month term of the contract starting on June 1, 2019. The Company previously announced on September 11, 2018 that 50,000 incentive stock options were granted to Mr. Staiger; no additional incentive stock options have been granted as part of SRC’s compensation.

(*) Non-IFRS Financial Measures:

Adjusted EBITDA is not a measure of financial performance under IFRS. We define Adjusted EBITDA as earnings before deducting amortization and depreciation, stock based compensation, foreign exchange gain or loss, finance expense or income, income tax expense and non-recurring impairment charges. This measure is not necessarily comparable to similarly titled measures used by other companies and should not be construed as an alternative to net income or cash flow from operating activities as determined in accordance with IFRS. Please refer to the discussion included in the Company’s interim MD&A for March 31, 2019 and annual MD&A for the year ended September 30, 2018.

About EnWave:

EnWave Corporation, a Vancouver-based advanced technology company, has developed Radiant Energy Vacuum (“REV™”) – an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV™ technology, shortening the time from harvest to marketable cannabis products. 

REV™ technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with industry leaders in multiple verticals for the use of REV™ technology. The company has signed over twenty royalty-bearing licenses to date, opening up nine distinct market sectors for commercialization of new and innovative products. In addition to these licenses, EnWave has formed a Limited Liability Corporation, NutraDried Food Company, LLC, to develop, manufacture, market and sell all-natural cheese snack products in the United States under the Moon Cheese® brand. 

EnWave has introduced REV™ as the new dehydration standard in the food and biological material sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently has three commercial REV™ platforms:

1.    nutraREV® which is used in the food industry to dry food products quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour;

2.    powderREV® which is used for the bulk dehydration of food cultures, probiotics and fine biochemicals such as enzymes below the freezing point, and

3.     quantaREV® which is used for continuous, high-volume low-temperature drying.

An additional platform, freezeREV®, is being developed as a new method to stabilize and dehydrate biopharmaceuticals such as vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation
Brent Charleton, CFA
President and CEO

For further information:

Brent Charleton, CFA, President and CEO at +1 (778) 378-9616
E-mail: bcharleton@enwave.net      

Dan Henriques, CPA, CA, Chief Financial Officer at +1 (604) 835-5212
E-mail: dhenriques@enwave.net

Deborah Honig, Corporate Development at +1 (647) 203-8793
E-mail: dhonig@enwave.net

Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All third party claims referred to in this release are not guaranteed to be accurate. All third party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.